{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-257388","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2026-06-04T20:06:56+00:00","discovered_at":"2026-06-04T20:07:31.283213+00:00","generated_at":"2026-06-04T20:29:24.606771+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Kalaris Therapeutics holds 2026 annual meeting; all proposals pass","bullets":["Elected Napoleone Ferrara, David Hallal, Leone Patterson as Class III directors (three-year terms).","Advisory vote on executive compensation approved: 15.85M for, 0.50M against.","Shareholders recommended say-on-pay every year; board adopts annual frequency.","Ratified Deloitte & Touche as auditor for FY 2026: 19.77M for, 1.58K against."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-257388","json":"https://secwatch.observer/filing/0001193125-26-257388.json","markdown":"https://secwatch.observer/filing/0001193125-26-257388.md","text":"https://secwatch.observer/filing/0001193125-26-257388.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526257388/0001193125-26-257388-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526257388/d85626d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T20:29:24.606771+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d2902802e2df9543abb0deca635fbdabe73e8e1f","claim":"Kalaris Therapeutics, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-03 meeting.","evidence_excerpt":"The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526257388/0001193125-26-257388-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-03"}],"fact_type":"shareholder_vote"},{"claim_id":"db50f3fcea3ce4ff7d1a8c65788463f90444e5ed","claim":"Kalaris Therapeutics, Inc. shareholders approved Advisory vote on the frequency of future advisory votes on executive compensation at the 2026-06-03 meeting.","evidence_excerpt":"The stockholders of the Company recommended, on a non-binding advisory basis, that future advisory votes on the compensation of the Company's named executive officers be held every year.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526257388/0001193125-26-257388-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-03"}],"fact_type":"shareholder_vote"},{"claim_id":"e3c1a59d1bc8d4c789e18998fd6582f30bbafffd","claim":"Kalaris Therapeutics, Inc. shareholders approved Election of Class III directors Napoleone Ferrara, M.D., David Hallal and Leone Patterson at the 2026-06-03 meeting.","evidence_excerpt":"The stockholders of the Company elected Napoleone Ferrara, M.D., David Hallal and Leone Patterson as Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526257388/0001193125-26-257388-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-03"}],"fact_type":"shareholder_vote"},{"claim_id":"e9b44fe1ffe6e429ca2c3dd369f6c8a11d1ee10b","claim":"Kalaris Therapeutics, Inc. shareholders approved Advisory vote on the compensation of the Company's named executive officers at the 2026-06-03 meeting.","evidence_excerpt":"The stockholders of the Company approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526257388/0001193125-26-257388-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-03"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}